- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
GSK and AstraZeneca are seeking FDA approval for new specialty medicines amid market competition.
1 report, 0 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK and AstraZeneca are seeking FDA approval for new specialty medicines amid market competition.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
AstraZeneca
British-Swedish pharmaceutical company
- FDA
Related events
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA is currently reviewing new drug applications for market entry.
Coverage
Newest first; wire copies grouped- Unknown outlet